Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Colvin Richard A

2. Date of Event Requiring Statement (MM/DD/YYYY) 8/22/2022

3. Issuer Name and Ticker or Trading Symbol

bluebird bio, Inc. [BLUE]

(Last) (First) (Middle)

C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Medical Officer /

(Street)

SOMERVILLE, MA 02145

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	693.00 ⁽¹⁾	D
Common Stock	1108.00 ⁽²⁾	D
Common Stock	3012.00 ⁽³⁾	D
Common Stock	15058.00 ⁽⁴⁾	D
Common Stock	13300.00 ⁽⁵⁾	D
Common Stock	11835.00	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (Right to buy)	⁽⁶⁾	11/1/2028	Common Stock	11134.00	$64.83	D
Stock Options (Right to buy)	⁽⁷⁾	3/2/2030	Common Stock	4429.00	$36.78	D
Stock Options (Right to buy)	⁽⁸⁾	2/16/2031	Common Stock	8030.00	$14.17	D
Stock Options (Right to buy)	⁽⁹⁾	3/1/2031	Common Stock	40153.00	$14.99	D
Stock Options (Right to buy)	⁽¹⁰⁾	2/1/2032	Common Stock	26400.00	$7.80	D

Explanation of Responses:
(1)	Restricted stock units for common stock vest over a four-year period at a rate of 25% on November 1, 2019, 25% on November 1, 2020, 25% on November 1, 2021, and 25% on November 1, 2022.
(2)	Restricted stock units for common stock vest over a four-year period at a rate of 25% on January 4, 2021, 25% on January 4, 2022, 25% on January 4, 2023, and 25% on January 4, 2024.
(3)	Restricted stock units for common stock vest over a four-year period at a rate of 25% on January 4, 2022, 25% on January 4, 2023, 25% on January 4, 2024, and 25% on January 4, 2025.
(4)	Restricted stock units for common stock vest over a four-year period at a rate of 25% on March 1, 2022, 25% on March 1, 2023, 25% on March 1, 2024, and 25% on March 1, 2025.
(5)	Restricted stock units for common stock vest over a four-year period at a rate of 25% on February 1, 2023, 25% on February 1, 2024, 25% on February 1, 2025, and 25% on February 1, 2026.
(6)	This option vests over a four-year period, at a rate of 25% on November 1, 2019, and in 36 equal monthly installments.
(7)	This option vests over a four-year period, at a rate of 25% on January 4, 2021, and in 36 equal monthly installments.
(8)	This option vests over a four-year period, at a rate of 25% on January 4, 2022 and in 36 equal monthly installments.
(9)	This option vests over a four-year period, at a rate of 25% on March 1, 2022, and in 36 equal monthly installments.
(10)	This option vests over a four-year period, at a rate of 25% on February 1, 2023, and in 36 equal monthly installments.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Colvin Richard A C/O BLUEBIRD BIO, INC 455 GRAND UNION BOULEVARD SOMERVILLE, MA 02145			Chief Medical Officer

Signatures
/s/ Helen C. Fu, Attorney-in-Fact		8/25/2022
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.